We showed, for the first time, that it was possible to accurately quantify FMRP in 3-mm-diameter newborn DBS disks which are used for state mandatory screening, and suggested that the Luminex immunoassay could serve as the first step in FXS screening of newborns and in at risk populations. The gene discussed is FMR1; the disease is fragile X syndrome.